Search results for "REMODELING"

showing 10 items of 357 documents

Bone Turnover Markers and Potential Correlation with Outcomes in Patients with Genitourinary Cancer (Renal and Bladder) and Bone Metastasis (Results …

2012

ABSTRACT Background Levels of bone turnover markers (BTM) might be correlated with outcome in terms of skeletal related events (SRE), disease progression and death. The aim of the study was to determine the possible correlation between BTM, disease progression, SREs and death in patients with genitourinary cancer and bone metastases (BM) treated with zoledronic acid (ZA). Methods Observational, prospective, multicenter study. Patients with genitourinary cancer (prostate, renal, bladder) and BM were included. BTM determined were: carboxiterminal telopeptide of type I collagen (β-CTX) and bone specific alkaline phosphatase (BALP) by ELISA (immunoenzymatic assay, IDS UK), and aminoterminal pro…

medicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationBone metastasisCancerHematologymedicine.diseaseLower riskGastroenterologyBone remodelingmedicine.anatomical_structureZoledronic acidOncologyN-terminal telopeptideProstateInternal medicinemedicinebusinesseducationmedicine.drugAnnals of Oncology
researchProduct

Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population

2021

Background: This study sought to investigate the prevalence and clinical outcome of left ventricular (LV) geometry in prediabetes and type 2 diabetes mellitus (T2DM) and the impact of glucose metabolism on the incidence of left ventricular hypertrophy (LVH). Methods: 15,010 subjects (35–74 years) of the population-based Gutenberg Health Study were categorized into euglycemia, prediabetes, and T2DM according to clinical and metabolic (HbA1c) information. Clinical outcome was assessed via structured follow-up. Results: The study comprised 12,121 individuals with euglycemia (81.6%), 1415 with prediabetes (9.5%), and 1316 with T2DM (8.9%). Prevalence of LVH increased from euglycemia (10.2%) ove…

medicine.medical_specialtyendocrine system diseasestype 2 diabetes mellitusPopulationprediabetesCarbohydrate metabolismleft ventricular concentric remodelingLeft ventricular hypertrophyArticleInternal medicineMedicineMass indexPrediabetescardiovascular diseaseseducationeducation.field_of_studybusiness.industryIncidence (epidemiology)Hazard ratioRType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseleft ventricular hypertrophyleft ventricular geometryCardiologyMedicinebusinessJournal of Clinical Medicine
researchProduct

Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secondary mitral regurgitation

2020

Abstract Aims Mitral annuloplasty using the Carillon Mitral Contour System (CMCS) reduces secondary mitral regurgitation (SMR) and leads to reverse left ventricular remodelling. The aim of this study was to evaluate the effect of the CMCS on the mitral valve annulus (MA) and left atrial volume (LAV). Methods and results We retrospectively evaluated the data of all patients treated with the CMCS at our centre. Using transthoracic echocardiography, MA diameters were assessed by measuring the anterolateral to posteromedial extend (ALPM) and the anterior to posterior (AP) dimensions, respectively. Also, LAV and left ventricular end‐diastolic volume (LVEDV) were assessed. Patients were examined …

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemMitral Valve AnnuloplastyCarillon030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineLeft atrialOriginal Research ArticlesInternal medicinemedicineHumansMitral Valve AnnulusOriginal Research Article030212 general & internal medicineMitral AnnuloplastyRetrospective StudiesMitral regurgitationbusiness.industryRemodellingMitral Valve InsufficiencyAtrial Remodelingmedicine.diseaseMitral valve annuluslcsh:RC666-701Heart failureTranscatheterPMVRCardiologyMitral ValveCardiology and Cardiovascular MedicinebusinessLAVPaired AnalysisESC Heart Failure
researchProduct

Ibandronic acid subsequent to raloxifene: Effect on bone metabolism and on cardiovascular risk factors

2015

s / Maturitas 81 (2015) 144–190 161 Materials andmethods: This randomized double-blind clinical trialwas carried out inAhvaz (Iran) fromAugust toDecember 2010. Forty postmenopausal women with symptoms of vaginal atrophy were randomly allocated to two groups to take vaginal suppositories of either 5mg hyaluronic acid sodium salt (n=20) or 1mg vitamin E (n=20) for 8 weeks. The symptoms of vaginal atrophy were evaluated by a self-assessed 4-point scale and the composite score was determined as none, mild, moderate, and severe in four periods. Results: The results showed that the symptoms were relieved significantly in both groups (P<0.001). The relief of symptomswas significantly superior in t…

medicine.medical_specialtymedicine.drug_classbusiness.industryVitamin Emedicine.medical_treatmentCardiovascular risk factorsObstetrics and Gynecologymedicine.diseaseGastroenterologyIbandronic acidGeneral Biochemistry Genetics and Molecular BiologyBone remodelingchemistry.chemical_compoundEndocrinologychemistryEstrogenInternal medicineHyaluronic acidmedicineRaloxifeneVaginal atrophybusinessmedicine.drugMaturitas
researchProduct

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Cas…

2020

Abstract Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.

medicine.medical_specialtymedicine.medical_treatmentARNIlcsh:Medicineheart failureCase ReportheartCase Reports030204 cardiovascular system & hematologySacubitril03 medical and health sciences0302 clinical medicineInternal medicinemedicineEnalaprilVentricular remodelingReverse remodelingarrhythmic burdenremodelinglcsh:R5-920business.industrylcsh:RGeneral Medicinemedicine.diseaseImplantable cardioverter-defibrillatorfailureValsartan030220 oncology & carcinogenesisHeart failureCardiologylcsh:Medicine (General)businessSacubitril Valsartanmedicine.drugClinical Case Reports
researchProduct

The QRS narrowing index for easy and early identification of responder to cardiac resynchronization therapy.

2013

The rationale for cardiac resynchronization therapy (CRT) in patients with heart failure (HF) is based on the possibility of inducing substantial left ventricular reverse remodeling. It is well known that some of these patients don't benefit from this therapy (the so-called non-responders) [1,2]. No better predictors of a positive answer to CRT than pre-CRT QRS duration (QRSd) were found [3,4]. The aim of our study was to identify a parameter for an easy and early identification of responders to CRT. In this regard, according to Rickard et al., we identified and observed QRS index (QI), as an expression of electrical remodeling after CRT, and its relation with anatomic reverse remodeling, e…

medicine.medical_specialtymedicine.medical_treatmentPopulationCardiac resynchronization therapyCardiac Resynchronization TherapyElectrocardiographyQRS complexPredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseaseseducationHeart Failureeducation.field_of_studyIschemic cardiomyopathyEjection fractionVentricular RemodelingLeft bundle branch blockbusiness.industryAtrial fibrillationRight bundle branch blockmedicine.diseaseCardiac resynchronization therapy Heart failure ResponderTreatment OutcomeMultivariate Analysiscardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiology
researchProduct

The Effects of Sacubitril/Valsartan on Clinical, Biochemical and Echocardiographic Parameters in Patients with Heart Failure with Reduced Ejection Fr…

2019

Background: Sacubitril/valsartan has been shown to be superior to enalapril in reducing the risks of death and hospitalization for heart failure (HF). However, knowledge of the impact on cardiac performance remains limited. We sought to evaluate the effects of sacubitril/valsartan on clinical, biochemical and echocardiographic parameters in patients with heart failure and reduced ejection fraction (HFrEF). Methods: Sacubitril/valsartan was administered to 205 HFrEF patients. Results: Among 230 patients (mean age 59 &plusmn

medicine.medical_specialtymedicine.medical_treatmentheart failureHemodynamics030204 cardiovascular system & hematologyArticleSacubitril03 medical and health sciences0302 clinical medicinehemodynamicInternal medicinemedicineechocardiography030212 general & internal medicineEnalaprilremodelingEjection fractionbusiness.industryneprilysin inhibitionGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareValsartansacubitril/valsartanHeart failureCardiologyreduced ejection fractionDiureticbusinessNt-ProBNPSacubitril Valsartanmedicine.drugJournal of Clinical Medicine
researchProduct

Single and Synergistic Effects of Type 2 Cytokines on Eosinophils and Asthma Hallmarks

2020

Abstract The type 2 cytokines IL-5, IL-13, and IL-4 play an important role in the induction and progression of asthma. According to the Global Initiative for Asthma guidelines, blood eosinophil numbers are one marker that helps to guide treatment decisions in patients suffering from severe forms of asthma. Effects of type 2 cytokines were analyzed, alone or in combination, on eosinophils in blood and other compartments and on the development of asthma symptoms. C57BL/6 mice received a single intranasal application of equimolar amounts of IL-5, IL-13, and IL-4, alone or in combination. Numbers, activation state, and migratory behavior of eosinophils in bone marrow (BM), blood, lung, and bron…

medicine.medical_treatmentImmunologyMedizinMice03 medical and health sciencesTh2 Cells0302 clinical medicineMetaplasiamedicineAnimalsHumansImmunology and AllergyEosinophiliaLungCells CulturedAsthmaGoblet cellInterleukin-13Lungmedicine.diagnostic_testbusiness.industryrespiratory systemEosinophilmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsMice Inbred C57BLDisease Models AnimalBronchoalveolar lavagemedicine.anatomical_structureCytokineImmunologyAirway RemodelingFemaleInterleukin-4Interleukin-5medicine.symptombusiness030215 immunologyThe Journal of Immunology
researchProduct

The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases

2018

International audience; Among the numerous molecules that are being studied for their potential utility as biomarkers of cardiovascular diseases, much interest has been shown in the superfamily of tumor necrosis factor (TNF) receptors. Members of this family include osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor κB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). These signals may be expressed and regulated, and their functions could be involved in several physiological and pathological processes. The relationship between bone regulatory proteins and vascular biology has attracted attention, and it has been suggested that OPG may medi…

musculoskeletal diseases0301 basic medicinemedicine.medical_specialtyOsteoporosisInflammationDisease030204 cardiovascular system & hematologyBone remodeling03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemOsteoprotegerinInternal medicinemedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacology (medical)Vascular CalcificationReceptorPharmacologybiologyChemistryOsteoprotegerinmedicine.disease3. Good health030104 developmental biologyEndocrinologyCardiovascular DiseasesRANKLbiology.proteinTumor necrosis factor alphaBone Remodelingmedicine.symptomPharmacology &amp; Therapeutics
researchProduct

FRI0150 Mtor blockade by rapamycin decreases arthritis and spondylitis development and severity in hla-b27 transgenic rats

2018

Career situation of first and presenting author Student for a master or a PhD. Introduction TNF and IL-17A have been demonstrated as key inflammatory cytokines in Spondyloarthritis (SpA), whereas targeting bone remodeling remains an unmet clinical need in SpA. The mammalian target of rapamycin (mTOR) regulates IL-17 expression and osteogenesis and could therefore be a promising therapeutic target in SpA. Objectives To investigate if blockade of mTOR with rapamycin inhibits the pathological processes in inflammation and bone in SpA. Methods Cytokines were measured by ELISA in the supernatant from SpA patient PBMCs stimulated with anti-CD3/CD28, with various concentrations of rapamycin. SpA F…

musculoskeletal diseases030203 arthritis & rheumatologyHLA-B27business.industryArthritis030209 endocrinology & metabolismInflammationPharmacologymedicine.diseaseBlockadeProinflammatory cytokineBone remodeling03 medical and health sciences0302 clinical medicinemedicineTumor necrosis factor alphamedicine.symptombusinessPI3K/AKT/mTOR pathwayFRIDAY, 15 JUNE 2018
researchProduct